Name: SMIP004
Price: 352.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    IC50 Value: 1.09 uM (MTT assay in LNCaP-S14 cells) [1]
    SMIP004 (N-(4-butyl-2-methyl-phenyl) acetamide) is a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells. Unlike SMIP001, SMIP004 was found to downregulate SKP2 and to stabilize p27, although neither SMIP is a proteasome inhibitor.
    in vitro: Whereas SMIP012 and 016 were moderately toxic in normal fibroblasts, SMIPs 001 and 004 showed substantial cancer cell specificity being at least five times more potent in LNCaP-S14 than in IMR90 cells , treatment with either MG132 or SMIP004 increased p27 half-life to > 6 h [1]. Both SMIP001 and 004 led to a strong increase in the recruitment of p27 to CDK2, while SMIP001 also slightly increased coprecipitation of p21. SMIP004 also reduced the amounts of cyclins E and A retrieved with CDK2. This was paralleled by a marked downregulation of cyclins E and A upon SMIP004 treatment. SMIP004 decreased the levels of positive cell cycle regulators, upregulated cyclin-dependent kinase inhibitors, and resulted in G1 arrest, inhibition of colony formation in soft agar, and cell death [2].
    in vivo: SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in mice [2].
    Clinical trial: N/A
- Properties
  - Categories
    
    Apoptosis inducer
    
    Alternative Name
    
    SMIP 004;SMIP-004; N-(4-butyl-2-methylphenyl)acetamide
    
    CAS Number
    
    143360-00-3
    
    Molecular Formula
    
    C13H19NO
    
    Molecular Weight
    
    205.3
    
    Appearance
    
    A solid
    
    Purity
    
    98.00%
    
    Solubility
    
    insoluble in H2O; ≥20.5 mg/mL in DMSO; ≥53.6 mg/mL in EtOH with ultrasonic
    
    Storage
    
    Store at -20°C
    
    SMILES
    
    CCCCC1=CC(=C(C=C1)NC(=O)C)C
    
    * For Research Use Only